It might pull it off, provided several things fall right in place.

Data show high levels of short interest in 10 stocks, including Avis Budget, RH, Lucid and CleanSpar

Fresh short‑interest data for late June shows a tightly packed group of mid‑ and large‑cap names whe

U.S. stocks rose, with the Dow Jones gaining 200 points on Wed. Jabil Inc (JBL) shares surged 9.8% a

Citizens analyst Silvan Turkcan reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Market Outp

Wedbush analyst David Nierengarten reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Neutral

Intellia shares rise after new Phase 3 lonvo-z data showed significant reductions in HAE attacks and

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Intellia Therapeutics (NASDAQ:NTLA)

Data from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European A

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolution

Intellia will also have a poster presentation detailing the burdens experienced by HAE patients livi

Bernstein analyst William Pickering maintains Intellia Therapeutics (NASDAQ:NTLA) with a Market P

Top Wall Street analysts updated their ratings on top companies. For full list of changes, including

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Intellia Therapeutics (NASDAQ:NTLA)

Canaccord Genuity analyst Whitney Ijem maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy a

Wedbush analyst David Nierengarten reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Neutral

Intellia Therapeutics (NASDAQ:NTLA) reported quarterly losses of $(0.81) per share which beat the an

Intellia Therapeutics (NASDAQ:NTLA) reported quarterly losses of $(0.81) per share which beat the an

Cathie Wood trims chip exposure and adds AI platform and biotech bets, offering ETF investors insigh

U.S. stock futures up, Nasdaq 100 gains 100 points. Robinhood shares fall 10.7% after reporting lowe

Canaccord Genuity analyst Whitney Ijem maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy a

Goldman Sachs analyst Salveen Richter maintains Intellia Therapeutics (NASDAQ:NTLA) with a Sell a

Citizens analyst Silvan Turkcan maintains Intellia Therapeutics (NASDAQ:NTLA) with a Market Outpe

Morgan Stanley analyst Terence Flynn maintains Intellia Therapeutics (NASDAQ:NTLA) with a Equal-W

Organon & Co (OGN) jumped 14.8% in pre-market trading as Sun Pharma agreed to acquire the compan

Top analysts upgraded RPM, Dow, Intellia, Sempra, & Target stocks. See ratings & targets. Po

Benzinga's top Wall Street analysts changed outlook on these names: AVAV cut to $290, OCUL raise

The massive rotation currently unfolding within ARK Invest suggests that Cathie Wood thinks 2026 wil

Here's a look at the top ten most shorted stocks in the market right now, including Wendy's,

Intellia Therapeutics (NASDAQ: NTLA) paused their Phase 3 MAGNITUDE and MAGNITUDE-2 trials after a s